CLX

Business profile & competitive position

The Clorox Company is classified in the Consumer Defensive sector and the Household & Personal Products industry. It operates as a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in about 25 countries, and sales in roughly 95 markets. Its consumer-facing brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional line is sold under Purell, CloroxPro, and Clorox Healthcare.

The portfolio is built around repeat-purchase staples and cleaning/health products, categories that typically enjoy steady demand through economic cycles. However, the numbers show a more complicated picture than “boring defensive compounder.” With a net margin of 8.7% and a P/E of 17.4, profitability is respectable but not elite for household products. The headline ROE of -1,893.5% looks alarming at first glance, but it is best read as a balance-sheet artifact—likely driven by negative or near-zero shareholders’ equity from buybacks and liabilities rather than operating insolvency. Meanwhile, a beta of 0.57 confirms the stock has less market sensitivity than the average equity, which is consistent with a defensive consumer franchise.

Competitive positioning also needs to account for distribution power. Clorox’s top five customers represented about half of fiscal 2026 net sales, and Walmart alone accounted for 26%. That concentration can support volume but also constrains pricing flexibility, because a handful of retailers control meaningful shelf access.

Financial posture

Clorox currently carries a market capitalization of $10.2 billion and trades at a trailing P/E of 17.4. The 8.7% net margin leaves a buffer, but it is not especially wide for a business selling branded consumer goods—input-cost pressure and trade-promotion spending can move it meaningfully. The deeply negative ROE does not signal a cash-flow problem in itself; it is a mechanical ratio that can spike when equity is low or negative, which can happen after sustained share repurchases or balance-sheet restructuring.

On a market basis, the stock was at $84.05 as of the snapshot date, below its 50-day exponential moving average of $89.80, with an RSI of 43.5—neither overbought nor deeply oversold. A recent Fool.com headline dated October 12, 2026, highlighted a dividend yield of 6% and an October 28 record date, reflecting why income-focused investors are watching the name closely despite the mixed operating performance.

Strategic priorities & outlook

Clorox’s most recent 10-K lays out several near-term operational priorities. The company is executing its IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation, aimed at generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building. It is also investing in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company capable of delivering consistent, profitable growth.

A major theme is health and hygiene expansion. In April 2026, Clorox completed the acquisition of GOJO Industries, expanding its health and hygiene portfolio and strengthening its business-to-business presence. Integrating GOJO and growing professional and institutional markets is a clear priority. At the same time, fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly because macroeconomic headwinds and the timing of the ERP transition had pulled some sales into fiscal 2025.

Two other facts are worth monitoring. First, the customer concentration noted earlier means execution with Walmart and other large retailers will have an outsized impact on results. Second, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox is exposed to several macro channels. The business relies on commodity inputs such as resins for Glad products, chemicals and fragrances for cleaning goods, packaging materials, and fuel-related freight costs. Movements in those input prices directly affect gross-margin potential, even though consumer-staples demand itself is relatively inelastic.

Regulatory risk is also inherent in this industry. Disinfectant and cleaning-product claims fall under EPA oversight, while labeling, advertising, and consumer-safety rules involve FTC and FDA scrutiny depending on the product. Health and hygiene expansion—especially through the GOJO/Purell professional channels—may add institutional and healthcare compliance requirements.

Because Clorox sells in about 95 markets, currency translation can affect reported results. Trade policy, tariffs on imported raw materials or packaging, and supply-chain disruptions are additional variables. Finally, intense private-label competition and the pricing leverage of massive retailers like Walmart create ongoing margin pressure, even when volumes remain stable.

Recent developments

Recent headlines have highlighted Clorox’s income profile and relative valuation. On October 12, 2026, Fool.com reported that investors needed to own Clorox by October 28 to qualify for its next dividend, describing the stock as yielding 6%. On October 10, 2026, Seeking Alpha included Clorox among “2 Dividend Kings Looking Dirt Cheap.” On October 6, 2026, Zacks published “Colgate vs. Clorox: Which Consumer Staples Giant Holds the Edge?”—a reminder that investors are actively comparing staples names in this valuation environment. A separate October 7, 2026 headline about Calnex and VIAVI expanding a networking partnership also appeared in the same news feed, though it is not directly related to Clorox’s operations.

Earnings behavior & post-earnings drift

Clorox has a solid recent earnings record. Over the last eight reported quarters, the company has beaten expectations 6 out of 8 times (75%), with an average earnings surprise of 9.6%. The average five-day price move following those reports was +1.67%, classified as an upward post-earnings drift.

The most recent quarters, however, show that beats do not always produce immediate rallies. For the August 3, 2026 report, Clorox posted EPS of $1.66 versus a $1.64 estimate (a 1.2% beat), and the stock rose 6.52% the next day and 9.61% over the following five days. The April 30, 2026 quarter was stronger on the bottom line—$1.64 actual versus $1.55 estimated, a 5.8% beat—but the stock fell 9.67% the next day and 4.49% over five days, suggesting the market’s real expectation involved guidance or margins as much as the headline number.

The February 3, 2026 quarter was a miss: EPS of $1.39 against a $1.43 estimate (-2.8% surprise), yet the stock climbed 2.43% the next day and 5.63% over five days. The November 3, 2025 report delivered $0.85 versus $0.818 estimated (3.9% beat), with a 1.17% next-day gain but a 4.08% five-day decline.

The next scheduled report is November 3, 2026, after the market close, with a consensus EPS estimate of $1.09. The average positive five-day drift provides historical context, but individual reports can still generate large next-day reversals, and the current stock price of $84.05 sits below the 50-day EMA of $89.80.